GALDY (Galderma Group AG) Beneish M-Score: -2.66 (As of Jun. 26, 2026)


GALDY Galderma Group AG GALDY
21 GF Score
Price $44.02
! 4 Warning Signs
View Full Analysis

What is Galderma Group AG Beneish M-Score?

Galderma Group AG GALDY -0.46% 21 Beneish M-Score is -2.66 as of Jun. 26, 2026. GuruFocus rates GALDY with a GF Score™ of 21/100. The stock has 4 warning signs investors should review. Among 911 Drug Manufacturers companies, Galderma Group AG ranks better than 64.43% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.66 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Galderma Group AG's Beneish M-Score or its related term are showing as below:

GALDY' s Beneish M-Score Range Over the Past 10 Years
Min: -2.66   Med: -2.47   Max: -2.27
Current: -2.66

During the past 5 years, the highest Beneish M-Score of Galderma Group AG was -2.27. The lowest was -2.66. And the median was -2.47.

Galderma Group AG Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Galderma Group AG's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG Beneish M-Score Chart

Galderma Group AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
0.00 0.00 0.00 -2.27 -2.66

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial 0.00 0.00 -2.27 0.00 -2.66

GALDY vs ZTS, UTHR, VTRS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galderma Group AG Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Galderma Group AG's Beneish M-Score falls into.


GALDY
21GF Score
Galderma Group AG GALDY
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galderma Group AG Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Galderma Group AG for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9896+0.528 * 1.009+0.404 * 0.9435+0.892 * 1.1804+0.115 * 1.1112
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9793+4.679 * -0.042709-0.327 * 1.0511
=-2.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was $1,063 Mil.
Revenue was $5,241 Mil.
Gross Profit was $3,609 Mil.
Total Current Assets was $2,437 Mil.
Total Assets was $13,393 Mil.
Property, Plant and Equipment(Net PPE) was $744 Mil.
Depreciation, Depletion and Amortization(DDA) was $323 Mil.
Selling, General, & Admin. Expense(SGA) was $2,372 Mil.
Total Current Liabilities was $2,055 Mil.
Long-Term Debt & Capital Lease Obligation was $2,689 Mil.
Net Income was $613 Mil.
Gross Profit was $0 Mil.
Cash Flow from Operations was $1,185 Mil.
 Total Receivables was $910 Mil.
Revenue was $4,440 Mil.
Gross Profit was $3,085 Mil.
Total Current Assets was $1,843 Mil.
Total Assets was $12,617 Mil.
Property, Plant and Equipment(Net PPE) was $578 Mil.
Depreciation, Depletion and Amortization(DDA) was $293 Mil.
Selling, General, & Admin. Expense(SGA) was $2,052 Mil.
Total Current Liabilities was $1,528 Mil.
Long-Term Debt & Capital Lease Obligation was $2,724 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1063 / 5241) / (910 / 4440)
=0.202824 / 0.204955
=0.9896

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3085 / 4440) / (3609 / 5241)
=0.69482 / 0.688609
=1.009

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2437 + 744) / 13393) / (1 - (1843 + 578) / 12617)
=0.762488 / 0.808116
=0.9435

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=5241 / 4440
=1.1804

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(293 / (293 + 578)) / (323 / (323 + 744))
=0.336395 / 0.302718
=1.1112

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2372 / 5241) / (2052 / 4440)
=0.452585 / 0.462162
=0.9793

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2689 + 2055) / 13393) / ((2724 + 1528) / 12617)
=0.354215 / 0.337006
=1.0511

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(613 - 0 - 1185) / 13393
=-0.042709

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Galderma Group AG has a M-score of -2.55 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.66 mean?
Galderma Group AG (GALDY) has a Beneish M-Score of -2.66 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Galderma Group AG and its competitors. According to the industry distribution chart, Galderma Group AG ranks #324 out of 911 companies in the Drug Manufacturers industry, placing it in the top 35.6%.
Is Galderma Group AG's Beneish M-Score too high?
Galderma Group AG's current Beneish M-Score is -2.66. Based on the distribution chart, Galderma Group AG ranks #324 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Galderma Group AG has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #324 out of 911 companies for Beneish M-Score. This puts Galderma Group AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Galderma Group AG and its competitors. Galderma Group AG's current Beneish M-Score is -2.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (GALDY) has a current Beneish M-Score of -2.66. The current Beneish M-Score is -2.66. Galderma Group AG's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Galderma Group AG (GALDY), the current Beneish M-Score is -2.66 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galderma Group AG Business Description

Address Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
21GF Score

Get the complete analysis for GALDY

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$44.02
Price